Skip to main content

Table 3 Payer coverage criteria for nusinersen for spinal muscular atrophy

From: Patients’ access to rare neuromuscular disease therapies varies across US private insurers

 

Plan imposes additional coverage criteria

Covered types of SMA

Required number of copies of SMN2 gene

Age requirement at treatment initiation

Ventilation requirements*

Motor function requirements

Prescriber requirement

Plan 1

Yes

1, 2, or 3

NA

 ≤ 15 years

Patient is not ventilator dependent*

NA

Neurologist with expertise in SMA

Plan 2

Yes

NA

1 or 2 copies

NA

NA

NA

NA

Plan 3

Yes

1, 2, or 3

NA

NA

NA

NA

Neurologist

Plan 4

Yes

NA

NA

NA

NA

NA

Neurologist

Plan 5

Yes

1, 2, or 3

NA

 ≤ 14 years

Patient is not ventilator dependent*

NA

Neurologist with expertise in SMA

Plan 6

Yes

NA

 ≥ 2 copies

NA

NA

NA

Neurologist

Plan 7

Yes

1, 2, or 3

NA

NA

NA

Member retains meaningful voluntary motor function

NA

Plan 8

Yes

1, 2, or 3

1, 2, or 3 copies

NA

NA

Member retains meaningful voluntary motor function

NA

Plan 9

Yes

1, 2, or 3

NA

NA

Not dependent for > 6 h a day

NA

Neurologist with expertise in SMA

Plan 10

Yes

1, 2, or 3

1, 2, 3, or 4 copies

NA

Patient is not ventilator dependent*

NA

NA

Plan 11

Yes

1, 2, or 3

NA

 ≤ 15 years

Patient is not ventilator dependent*

Member retains meaningful voluntary motor function

Neurologist

Plan 12

Yes

1, 2, or 3

1 or 2 copies

 ≤ 15 years

Not dependent for > 12 h a day

NA

Neurologist with expertise in SMA

Plan 13

No policy

1, 2, or 3

NA

 ≤ 15 years

NA

NA

NA

Plan 14

Yes

1, 2, or 3

Symptomatic patients: 2, 3, or 4 copies;

Asymptomatic patients: 2 or 3 copies

 ≤ 15 years

Patient is not ventilator dependent*

NA

Neurologist with expertise in SMA

Plan 15

Yes

NA

Early onset: 1 or 2 copies; Late onset: 1, 2, or 3 copies

NA

NA

NA

NA

Plan 16

Yes

1, 2, or 3

NA

NA

NA

NA

Neurologist

Plan 17

Yes

1, 2, or 3

 ≥ 2 copies

NA

Patient is not ventilator dependent*

NA

Neurologist with expertise in SMA

  1. NA = Payer did not address criterion in their coverage policy; *Permanent ventilation (defined as tracheostomy or ventilatory support for at least 16 h per day for more than 21 continuous days in the absence of an acute reversible event); Meaningful motor function typically defined as the ability to manipulate objects using upper extremities, walk, etc.
  2. NA not available, SMA spinal muscular atrophy, SMN survival motor neuron